Menopause

Astellas has announced positive results of a trial evaluating the safety and efficacy of fezolinetant in menopausal women with moderate to severe vasomotor symptoms.

Monica Christmas, MD, associate professor at the University of Chicago, discusses the findings of a study on how vaginal estrogen may be used to treat urinary symptoms in postmenopausal women, along with how she hopes these findings will impact treatment in women with urinary symptoms.

As maintaining cognitive function remains difficult in an aging population, how are women in menopause impacted?

In a recent review, vaginal estrogen was effective for treating urinary symptoms in postmenopausal women.

The North American Menopause Society Advisory Panel has announced the release of their 2023 position statement on nonhormonal therapy for menopause.

In a recent study, midlife women with prediabetes before menopause transition were more likely to experience fractures in postmenopause.

At the 2023 ACOG Annual Clinical & Scientific Meeting, the safety and efficacy of compounded bioidentical hormone therapy for menopause were discussed.

At the 2023 ACOG Annual Clinical & Scientific Meeting, Gloria Richard-Davis MD, MBA, NCMP, FACOG, discussed the importance of using hormone therapies to treat menopause symptoms.

Genevieve Neal-Perry, MD, PhD, talks about the recent approval of fezolinetant (Veozah; Astellas Pharma) and her latest phase 3 research presented at the 2023 ACOG Annual Clinical and Scientific Meeting.

Fezolinetant (Veozah; Astellas Pharma) is now the first neurokinin 3 receptor antagonist approved for the treatment of vasomotor symptoms associated with menopause.

What the obstetrician-gynecologist should know

In a recent study, menopausal vasomotor symptoms were successfully treated using the selective neurokinin-1,3 receptor antagonist elinzanetant (Bayer).

Multiple hormonal and non-hormonal therapies are available for treating genitourinary syndrome of menopause in breast cancer survivors, but combination therapies are the most effective.

In a recent study, menopause was associated with an estimated annual financial loss of $1.8 billion in work time and $26.6 billion in medical costs in the United States.

In a recent study, female reproductive hormone concentration and age at menopause were impacted by smoking, alcohol, and coffee consumption.

In a recent phase 1 trial, DARE-HRT1 showed positive safety and acceptability results for treating moderate-to-severe vasomotor symptoms in postmenopausal women.

A literature review found that although hormonal therapy with estrogen is the first-line therapy for bothersome vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM) symptoms, nonhormonal medications such as paroxetine and venlafaxine can also be effective for VMS.

A recent study showed an association between menopause and increased glaucoma risk, with a potential for estrogen-based treatment.

In a recent study, women who received risk-reducing salpingo-oophorectomy when premenopausal more often experienced discomfort during sexual activity and vaginal dryness than those receiving it when postmenopausal.

An analysis of perimenopausal women with rheumatoid arthritis indicated that patients receiving exogenous sex hormones more frequently achieved SDAI- and CDAI-defined remission.

Newly published data from a phase 3 study demonstrate the safety and efficacy of fezolinetant (Astellas) for treatment of VMS due to menopause.

At the International Society for the Study of Women’s Sexual Health conference, held March 2 through 5 in St. Louis, Missouri, Michael Krychman, digital editor for Contemporary OB/GYN® talked with Barb Dehn, NP, from El Camino Women’s Medical Group in Mountain View, California, about the importance of helping professional women cope with menopause.

A look at vaginal laser surgery for overactive bladder syndrome.

A new study suggests that ospemifene can reduce harmful bacteria and significantly contribute to vaginal health in postmenopausal women.

Investigators identify a strong association between exposure to air pollution and bone mineral loss in postmenopausal women.